Astrazeneca-Phar Stock/Share Prices, Buy and Sell Astrazeneca-Phar BSE Stocks

Market Snapshot

BSE Sensex: 41613.19 0.55%
BSE 500: 16013.34 0.60%
BSE 200: 5163.01 0.61%
BSE 100: 12382.17 0.58%
BSE Mid-Cap: 15822.54 0.77%
BSE Small-Cap: 14845.96 0.50%
BANKEX: 35667.71 0.92%
BSE IT Sector: 16233.99 0.02%
Nifty 50: 12248.25 0.56%
Nifty 500: 10083.7 0.62%
Nifty 200: 6358.1 0.64%
Nifty 100: 12386.95 0.60%
Nifty Midcap 100: 18357.2 0.92%
Nifty Small 100: 6345.05 0.79%
Nifty IT: 16472.75 -0.01%
Nifty PSU Bank: 2446.3 0.34%

News:

Info Edge soars on launching R...
Zensar Technologies Ltd leads ...
Hindustan Fluoro Carbons Ltd l...
Ultratech Cement firms up afte...
Volumes spurt at Sheela Foam L...

Astrazeneca Pharma India Ltd NSE / BSE
Pharmaceuticals, Small Cap

Invest

24 Jan 2020 | 04:00 PM

2,515.55

-15.80 (-0.62%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

55.7%

Return (1Y)

Beaten S&P BSE Healthcare by 55.43%
More Volatile

2.59%

Standard Deviation (1Y)

Higher than S&P BSE Healthcare by 1.71%
Not so consistent

5/12

Months

underperformed S&P BSE Healthcare
AxisDirect View

No View

52 Week High-Low

2,927

1,555

News & Announcements

Astrazeneca Pharma India to hold board meeting
4 days ago

Astrazeneca Pharma India to hold board meeting

22 - Jan - 2020 12:00 AM | 4 days ago

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 3 February 2020.
Powered by Capital Market - Live News
Astrazeneca Pharma India standalone net profit rises 57.94% in the September 2019 quarter
76 days ago

Astrazeneca Pharma India standalone net profit rises 57.94% in the September 2019 quarter

11 - Nov - 2019 12:00 AM | 76 days ago

Net profit of Astrazeneca Pharma India rose 57.94% to Rs 14.42 crore in the quarter ended September 2019 as against Rs 9.13 crore during the previous quarter ended September 2018. Sales rose 29.20% to Rs 208.48 crore in the quarter ended September 2019 as against Rs 161.36 crore during the previous quarter ended September 2018.
Particulars Quarter Ended
Sep. 2019 Sep. 2018 % Var.
Sales 208.48 161.36 29
OPM % 16.10 9.15 -
PBDT 36.44 18.11 101
PBT 31.80 14.44 120
NP 14.42 9.13 58
Powered by Capital Market - Live News
Astrazeneca Pharma India to convene board meeting
89 days ago

Astrazeneca Pharma India to convene board meeting

29 - Oct - 2019 12:00 AM | 89 days ago

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 11 November 2019.
Powered by Capital Market - Live News
Astrazeneca Pharma gains after DGCA approves anti-diabetic drug
122 days ago

Astrazeneca Pharma gains after DGCA approves anti-diabetic drug

26 - Sep - 2019 12:00 AM | 122 days ago

AstraZeneca Pharma India announced after market hours yesterday, 25 September 2019, that it received import and market permission in Form 45 (marketing authorization) from the Drugs Controller General of India (DGCA) for fixed dose combination (FDC) of dapagliflozin 10mg + saxagliptin 5mg film coated tablets.
The receipt of this import and market permission paves way for the launch of FDC of dapagliflozin 10mg + saxagliptin 5mg film coated tablets (QTERN) in India, subject to the receipt of other related statutory approvals and licenses.
QTERN is a prescription medicine that contains dapagliflozin and saxagliptin. QTERN is used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes.
Meanwhile, the S&P BSE Sensex was up 421 points or 1.09% to 39014.31.
On the BSE, 759 shares were traded in the Astrazeneca Pharma counter so far compared with average daily volumes of 1629 shares in the past one quarter. The stock hit a high of Rs 2216.85 and a low of Rs 2185.1 so far during the day.
The stock hit a 52-week high of Rs 2398.55 on 30 Apr 2019. The stock hit a 52-week low of Rs 1306.8 on 07 Dec 2018.
Astrazen's net profit rose 236.8% to Rs 21.52 crore on a 26.7% increase in net sales to Rs 204.56 crore in Q1 June 2019 over Q1 June 2018.
AstraZeneca Pharma India (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India. It is a subsidiary of AstraZeneca Plc, UK. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular and & metabolic diseases, oncology and respiratory.
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Astrazeneca Pharma India Ltd has decreased by -25.26% since past 3 Months
MF shareholding in Astrazeneca Pharma India Ltd has increased by 9.95% since past 3 Months
FII shareholding in Astrazeneca Pharma India Ltd has increased by 246.72% since past 1 Year
MF shareholding in Astrazeneca Pharma India Ltd has decreased by -36.93% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Sep. 2019	Sep. 2018	% Var.
Sales	208.48	161.36	29
OPM %	16.10	9.15	-
PBDT	36.44	18.11	101
PBT	31.80	14.44	120
NP	14.42	9.13	58

General Notifications

My Notifications

Research Notifications

Astrazeneca Pharma India Ltd NSE / BSE Pharmaceuticals, Small Cap

2,515.55 -15.80 (-0.62%)

News & Announcements

Price vs Volume

Stock Trivia

Astrazeneca Pharma India Ltd NSE / BSE
Pharmaceuticals, Small Cap

2,515.55

-15.80 (-0.62%)